Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Was This Acquisition a Smart Move for GlaxoSmithKline?
Was This Acquisition a Smart Move for GlaxoSmithKline?
Was This Acquisition a Smart Move for GlaxoSmithKline?
Submitted by
admin
on May 15, 2022 - 11:10pm
Source:
Motley Fool
News Tags:
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
Headline:
Was This Acquisition a Smart Move for GlaxoSmithKline?
snippet:
Momelotinib could be a potent treatment for bone marrow cancer patients.
The drug candidate could also become a blockbuster for GlaxoSmithKline.
Shares of the drugmaker seems like a good long-term buy for investors.
Do Not Allow Advertisers to Use My Personal information